Answers are grounded in this paper and cite their sources.
Hypervirulent Klebsiella pneumoniae (hvKP) variants represent urgent multidrug-resistant threats against which no licensed vaccine exists. FimA is indispensable for KP mucosal colonization and is thus a promising vaccine target; however, its protective immunodominant B-cell epitopes in vaccines with different adjuvants against KP remain undefined. Here, we revealed how adjuvants shape different hierarchies of the immunodominant B-cell epitopes of FimA and studied the humoral anti-FimA response and protective efficacy in a murine model of acute pneumonia. BALB/c mice were intramuscularly immunized with recombinant FimA formulated in three clinically trialed adjuvants: AddaVax, AddaS03, and AlPO 4 , whereafter they were challenged with lethal doses of the hvKP YBQ strain. Under the experimental conditions used in this immunization-challenge model, AddaS03-immunized mice exhibited 100% survival and reduced pulmonary bacterial load, whereas AddaVax-immunized mice showed only 40% survival. Furthermore, FimA-immunized groups with different adjuvants exhibited different opsonophagocytic killing activities and inflammatory cytokine levels, likely explaining the variability in protective immunity. ELISA-based linear B-cell epitope mapping of FimA with different adjuvants revealed three novel immunodominant epitopes—their hierarchies were altered by different adjuvants. Further, a causal link might exist between FimA epitope hierarchy and protective efficacy in hvKP-infected mice. Immunization with a mixture of these FimA immunodominant epitopes plus AlPO 4 achieved an 80% protection rate, where it exerted a potent therapeutic effect in combination with low-dose meropenem. Our findings revealed that adjuvants enhance anti-FimA immunity and modulate FimA epitope hierarchies across different vaccinated groups. Therefore, rational adjuvant selection may elicit effective FimA-induced responses in KP vaccines, wherein different FimA immunodominant epitopes induce protective humoral immune responses.
No takes yet. Share an insight, caveat, or question.
Ming et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: